KPIs & Operating Metrics(New)
Balance Sheet
Daily Values
Growth Metrics
Income Statement
Others
Non-Current ReceivablesReceivables - NetReceivables - OtherReceivables Refunds
Ratios

Novartis Ag (NVS) Receivables - Other (2017 - 2025)

Novartis Ag's Receivables - Other history spans 9 years, with the latest figure at $1.1 billion for Q4 2025.

  • For Q4 2025, Receivables - Other rose 4.01% year-over-year to $1.1 billion; the TTM value through Dec 2025 reached $1.1 billion, up 4.01%, while the annual FY2025 figure was $1.1 billion, 4.01% up from the prior year.
  • Receivables - Other for Q4 2025 was $1.1 billion at Novartis Ag, up from $1.1 billion in the prior quarter.
  • Across five years, Receivables - Other topped out at $1.3 billion in Q4 2023 and bottomed at $793.0 million in Q4 2021.
  • The 5-year median for Receivables - Other is $1.1 billion (2024), against an average of $1.0 billion.
  • The largest annual shift saw Receivables - Other dropped 17.65% in 2021 before it skyrocketed 30.69% in 2023.
  • A 5-year view of Receivables - Other shows it stood at $793.0 million in 2021, then rose by 20.81% to $958.0 million in 2022, then surged by 30.69% to $1.3 billion in 2023, then decreased by 12.38% to $1.1 billion in 2024, then increased by 4.01% to $1.1 billion in 2025.
  • Per Business Quant, the three most recent readings for NVS's Receivables - Other are $1.1 billion (Q4 2025), $1.1 billion (Q4 2024), and $1.3 billion (Q4 2023).